1. Introduction
Intra-abdominal infections (IAI) represent a particular clinical challenge, as they differ from other types of infections in a number of aspects.[1] The clinical spectrum of IAI is very broad, ranging from uncomplicated acute appendicitis to generalized peritonitis caused by a perforated ischaemic bowel. Surgery – often referred to as surgical source control – is essential and generally considered to be a decisive factor for the outcome in patients with IAI.[2‐4] Source control is defined as the elimination of the source of infection and the control over ongoing contamination. This concept is based on the following principles: drainage of abscesses or contaminated fluid, debridement of necrotic tissue, and restoration of anatomy and function.[5] In addition, during surgery for gastrointestinal pathology, excision of diseased viscus, if feasible, and gastrointestinal diversion, if applicable, may limit the risk of anastomotic leakage and subsequent peritonitis. Source control may be achieved through laparotomy, laparoscopy and percutaneous drainage (ultrasound or CT guided). In the absence of perforation, operative intervention is generally not indicated.
The microbial aetiology and microbiological diagnosis pose another challenge. As the gastrointestinal tract contains a huge number of different micro-organisms, IAI is usually polymicrobial. Yet, not all bacteria can be isolated by means of routine cultures.[6] On the other hand, not all bacteria isolated represent true pathogens, as most enteric bacteria are of relatively low virulence. The profile of the patient determines the approach for IAI. Community-acquired IAI may be more rapidly diagnosed than that occurring in critically ill patients in whom signs and symptoms may be masked by other inflammatory processes. Critically ill patients also have more pronounced risk profiles, as IAI is more often associated with acute kidney injury and septic shock.[7] Furthermore, a healthcare origin of infection is important as there exists a higher likelihood of involvement of resistant pathogens with the potential for inappropriate empiric antimicrobial therapy and detrimental outcomes. In the present review, emphasis is given to empirical choices of antimicrobial therapy in patients with IAI. Special attention is given to the different elements that should be taken into account in order to select the proper regimen. Issues such as new agents and duration of therapy are mentioned briefly.
Anzeige
2. The Challenge of Definitions
2.1 Primary, Secondary and Tertiary Peritonitis/Complicated vs Non-Complicated Intra-Abdominal Infection (IAI)
Primary peritonitis includes distinct disease entities such as peritonitis in decompensated liver cirrhosis and peritonitis in nephrotic syndrome with ascites (e.g. with Streptococcus pneumoniae). These imply an intact gastrointestinal tract without overt barrier disruption. Secondary peritonitis refers to localized or generalized peritoneal inflammation and abscess formation due to disruption of the anatomical barrier (e.g. perforated appendicitis or diverticulitis). In the literature, so-called ‘tertiary peritonitis’ has been defined, referring to cases that cannot be solved by a single or even sequential surgical intervention, in combination with often sequential courses of antimicrobial therapy, either with or without antifungal coverage.[8] A suggested approach for these difficult-to-solve cases consisted of an open-abdomen treatment associated with chronic serositis and colonisation with often resistant pathogens. This definition refers to treatment failure in secondary peritonitis.
The most frequently used classification for IAI in randomized controlled trials of antimicrobial regimens distinguishes between ‘uncomplicated’ and ‘complicated’ IAI.[9] In uncomplicated IAI, the infectious process is contained within a single organ, without anatomical disruption. In most patients, these infections can be managed with surgical resection alone and, with the exception of peri-operative prophylaxis, no additional antimicrobial therapy is necessary. Acute appendicitis and cholecystitis are common examples of uncomplicated IAI.
In ‘complicated’ IAI, disease is extended with either localized or generalized peritonitis. These cases require a more prolonged course of antimicrobials following the surgical procedure.
In clinical trials, essentially only IAI with uneventful clinical courses are selected. Infections are categorized as complicated on the basis of the sole criterion of anatomical barrier disruption, and selected on the basis of often rigid inclusion and exclusion criteria for cases with mild to moderate disease severity. However, IAI comprises more than a single dimension of complexity. In the mind of clinicians, ‘complicated’ may refer to severity of disease expression, anatomical extent of the infectious process and the involvement of resistant pathogens. Hence, the literature has been contaminated with this bias.
Anzeige
2.2 An Alternative Categorization of IAI
As the current classifications of IAI often incite confusion by mixing elements of anatomical barrier disruption, severity of disease expression and (the likelihood of) resistance involvement, we propose an alternative. We suggest abandoning the terms ‘uncomplicated’ and ‘complicated’ IAI, as they merely confuse the issue. Furthermore, the term ‘tertiary peritonitis’ should likewise be discarded, as this simply refers to treatment failure of secondary peritonitis resulting in a state of persistent infection and/or inflammation. Hence, anatomical disruption and disease severity should be separated into different phenotypes for the same disease (e. g. diverticulitis); this should then be combined with either presence or absence of risk factors for involvement of pathogens that are not routinely covered in first-line antimicrobial regimens (Pseudomonas aeruginosa, enterococci, Candida species and resistant pathogens). Generally, these risk factors can be reduced to recent exposure to antimicrobial agents and substantial length of stay in healthcare settings (5–7 days). As such, we developed a grid based on the different components in the classification: (i) anatomical disruption; (ii) severity of disease expression; and (iii) either community-acquired/early-onset healthcare-associated origin or late-onset healthcare-associated origin and/or recent antimicrobial exposure (table I).
Table I
Table I. Classification of intra-abdominal infections
The grid allows physicians to define the index case of IAI in a more unequivocal way and subsequently to select the most convenient empirical antimicrobial regimen (table II). As IAI basically always requires coverage against Gram-positive, Gram-negative and anaerobic bacteria, the grid more precisely advises on the necessity of covering nosocomial Gram-negative bacteria (including P. aeruginosa), enterococci, yeasts and resistant pathogens. The necessity of additionally covering these pathogens is based on the assessment of overall risk of treatment failure (according to the three components of the IAI classification). For example, the grid advises a baseline regimen for community-acquired IAI presenting with localized peritonitis and severe sepsis. However, should the patient present with either diffuse peritonitis and/or septic shock, the grid advises to additionally cover nosocomial Gram-negative bacteria and enterococci. This is because it is perceived as a grim clinical situation (more difficult surgical cleaning and/or presence of organ failure) in which the negative consequences of inappropriate antimicrobial therapy are close to inevitable. However, from a purely microbiological viewpoint, there is little to support this approach. The antimicrobial options provided by the grid are mainly based on clarity and simplicity, albeit however, that local epidemiology should always be considered as well (see section 3.2.1). The grid does not include the additional dimension of treatment failure. As such, it reflects the initial conditions of IAI presentation, similar to a severity of disease scoring system used as a prognostic indicator such as the APACHE II (Acute Physiology and Chronic Health Evaluation II) score reflecting the first 24 hours of disease presentation.[10] However, throughout this paper, we use the definitions used in individual publications.
Table II
Table II. Empirical antimicrobial coverage according to the classification of intra-abdominal infection in table I
×
![]()
×
![]()
3. Antimicrobial Therapy
3.1 General Considerations
The main objectives of antimicrobial therapy in the treatment of IAIs are to prevent local and haematogenous spread, and to reduce late complications. As for other infections, early administration of antibacterials is important, and it is logical that these are administered upon the diagnosis of complicated IAI. When preoperative imaging is unequivocal, treatment should not be delayed for intraoperative confirmation. Perioperative prophylaxis should not be used as an alternative or temporizing strategy in these patients: for patients with suspected IAI but equivocal findings who undergo explorative laparotomy, we advise the administration of antibacterials even without confirmation of IAI; when clinical syndrome and preoperative imaging are highly suggestive, treatment should not be delayed for intra-operative confirmation. This is a setting of early empirical treatment requiring high sensitivity for the diagnosis of complicated IAI at a certain cost for specificity, and not a setting of peri-operative prophylaxis. In critically ill patients, the threshold for starting antibacterials may be even lower, as the delayed treatment of infections is associated with considerable morbidity and mortality. Upon documentation of intra-abdominal pathology without infection, antibacterials should be discontinued.
Intravenous administration is the only route for early antimicrobial treatment in truly complicated IAI. Oral administration is to be avoided at that stage, as absorption will usually be unreliable, and the effect may be delayed. Postoperatively, oral administration may be considered with improvement of clinical condition and recovery of gastrointestinal function.
3.2 Factors to Take into Account when Selecting Empirical Antimicrobial Therapy for IAI
IAI are typically polymicrobial, and require empirical coverage for Gram-positive and Gram-negative, aerobic and anaerobic bacteria, with the latter most relevant for infections originating from the lower gastrointestinal tract (distal small bowel to rectum). Whether, in addition, coverage must be given for enterococci, P. aeruginosa, Candida species and resistant pathogens, such as extended-spectrum β-lactamase (ESBL)-producing Enterobacteriaceae, depends on microbiological issues, epidemiological patterns and patient-related factors.
3.2.1 Microbiological Considerations
The microbiology of IAI reflects a summary of transient or persistent normal gastrointestinal flora with potentially pathogenic micro-organisms. As such, the aetiology of IAI includes Gram-positive, Gram-negative and anaerobe bacteria as well as fungal species. However, about 20–25% of cultures in secondary peritonitis prove negative.[11] In another quarter of the patients, the infection is monomicrobial and, in half of the patients peritonitis is polymicrobial.[12] However, the precise mix of pathogens involved is highly variable depending on several factors that lead to the risk profile of the patient. Table III gives an overview of the most common causative pathogens in IAI. Interpretation of the extent of micro-organisms involved is hampered by the limited microbiological workup of anaerobe cultures in general practice. In principle, IAI are polymicrobial with an aerobic component (inducing local/systemic inflammation) and an anaerobic component (responsible for abscess formation).
Table III
Table III. Frequently isolated pathogens in complicated intra-abdominal infections
The value of microbiological identification is a matter of debate, as cultures often reveal mixed flora in which it is difficult to distinguish contaminants from true pathogens. In cases of community-acquired IAI with secondary peritonitis, cultures rarely influence the management of the patient as the encountered flora is generally susceptible to the standard regimens.[15] In cases of healthcare-associated IAI, peri-operative culturing is routinely indicated, as responsible pathogens are less predictable and more likely resistant to first-line or standard empirical regimens (amoxicillin/clavulanic acid or combination of cefuroxim plus a 5-nitroimidazole). In addition, peri-operative cultures may reveal other pathogens such as enterococci, P. aeruginosa or yeast, which are also not routinely covered by first-line antimicrobial regimens. As such, culture results allow for either correction of an initially inappropriate choice or de-escalation. However, irrespective of the isolated pathogens, coverage against Gram-positive, Gram-negative and anaerobic bacteria remains indicated. Besides adapting the empirically initiated antimicrobial therapy, culture results provide insights into local epidemiological patterns, which can be valuable in selecting the proper agents in the empirical phase.
Blood cultures are generally not recommended as they usually do not provide additional valuable information, especially in community-acquired cases. However, in cases with severe sepsis or septic shock, its use is mandatory.[16] Also, blood cultures positive for anaerobic bacteria, especially Bacteroides fragilis, in sepsis of unclear origin, are a strong indication of an intra-abdominal focus.[17] Systemic breakthrough as evidenced by positive blood culture represents fulminant infection, with a particularly grim prognosis.[18]
Location of Primary Source and Microbiology
Location of the primary source of secondary peritonitis influences the spectrum of pathogens involved, as stomach, upper small bowel, lower small bowel and large bowel have a distinct flora in terms of microbial species and density. Figure 1 summarizes initial culture results, according to the primary source of the IAI as found by de Ruiter et al.[19] There exists a preponderance of Gram-negative and anaerobic bacteria in IAI originating from colorectal sources or appendicitis. In gastro-duodenal perforation, Gram-positive bacteria and yeasts are isolated most frequently. In IAI from a small intestine source, there is a relative balance between the four different groups of pathogenic micro-organisms. However, in subsequent weeks there is a shift in culture results, showing an increase in Gram-positive bacteria, while the prevalence of Gram-negatives decreases.[19]
Fig. 1
Fig. 1 Initial culture results in secondary and tertiary peritonitis: percentages of positive cultures according to the primary source of infection.[19]
×
![]()
Healthcare-Associated vs Community-Acquired IAI
Healthcare-associated infection includes all circumstances in which patients have had close association with either acute or chronic care settings.[20] The relevance of the issue is that healthcare-associated IAI is inherently associated with an increased risk of resistant pathogen involvement. Based on a 10-year single-centre study of over 2000 cases of complicated IAI, Swenson et al.[21] found that resistant pathogens were isolated from 79% of healthcare-associated infections. The risk of involvement of resistant pathogens is, however, also the result of exposure to antibacterials, irrespective of having close association with healthcare facilities as mentioned in the definitions.[20] However, it should be mentioned that, in IAI occurring within the first days of hospitalization, the prevalence of resistant pathogens is not dramatically increased.[21,22] In Swenson et al.,[21] the average time between hospital admission and treatment of resistant pathogens was 10 days (13 days for non-fermenting Gram-negatives, 8 days for resistant staphylococci, 23 days for vancomycin-resistant enterococci [VRE] and 7 days for fungi). Also important, the average time from admission to treatment of non-resistant pathogens was still 5 days. Assuming that in these cases resistant pathogens were also cultured after about 5–7 days, these data indicate a timeframe within which resistant pathogens do not necessarily need to be covered in the empirical regimen. Of course, local epidemiological patterns should always be taken into account (e.g. quinolone resistance in Escherichia coli in the community). In nosocomial pneumonia, the risk of resistant pathogen involvement is also substantial after a hospitalization of about 5–7 days, leading to the concept of early-onset and late-onset infection.[23] In IAI, however, such a concept, although probably of value in the context of empirical choices within antimicrobials, is not proposed in the current guidelines, in which no difference is made in risk assessment of healthcare-associated IAI according to length of hospitalization.[24] In the proposed grid (table I), a distinction is made between community-acquired or early-onset healthcare-associated IAI (<5–7 days) and late-onset healthcare-associated IAI. Yet, recent exposure to antimicrobial agents must be considered as a risk factor for resistance, irrespective of origin of onset. Therefore, when it comes to selecting an empirical antimicrobial regimen, cases with community-onset IAI with recent antimicrobial exposure (≥2 days of therapy) are categorized together with late-onset healthcare-associated IAI.
Local Epidemiology of Resistance
Empirical choices of antimicrobial agents are based upon the risk assessment of involvement of resistant pathogens. In IAI literature, the concept of resistance goes beyond in vitro multidrug resistance and basically includes all pathogens not essentially covered by first-line empirical regimens. As such, the following micro-organisms are considered ‘resistant’: methicillin-resistant Staphylococcus aureus (MRSA), coagulase-negative staphylococci, VRE, ESBL-producing Enterobacteriaceae, quinolone-resistant E. coli, non-fermenting Gram-negative bacteria (including P. aeruginosa, Stenotrophomonas maltophilia, Acinetobacter baumannii) and yeasts.
Although the ongoing emergence of resistance is a global concern, it is local epidemiology data that should be taken into account as they can substantially differ from the national average.[25] For example, in a general hospital in Houston (TX, USA), the prevalence of fluoroquinolone-resistant E. coli was 2- to 4-fold higher than the national averages.[25] The increase of quinolone-resistant E. coli in community-acquired infections was mostly a matter of urinary isolates in male outpatients or in sputum samples from inpatients. Therefore, the extent to which this problem weighs on the specific aetiology of IAIs is uncertain. Large multicentre surveillance studies which focus on resistance are scarce in IAI and hence the true prevalence of resistance is hard to estimate. Regardless, it is unjustified to take national averages of ‘clinical specimens’ as a reference for aetiology in IAIs. Data from the European Antimicrobial Resistance Surveillance System indicate that, in France, about 22% of all clinical isolates of S. aureus tested (n = 4720) were resistant to methicillin.[26] In contrast, in a prospective study performed in 25 French centres, Montravers et al.[27] found not a single S. aureus isolate from nosocomial IAI to be methicillin resistant. So, although obviously present in other types of infection, MRSA is not a common pathogen in secondary peritonitis. An identical observation can be made for VRE. Although enterococci are important pathogens in IAI, as the overall prevalence of VRE is low, the role of VRE is limited to exceptional cases with late disease and to risk groups such as complicated liver transplantation.[22,27‐29] As such, in the majority of IAI, including community-acquired and early secondary peritonitis, enterococci and, in particular circumstances, VRE, do not need to be covered in the empirical regimen.
The need to cover ESBL Enterobacteriaceae in community-acquired IAI is also strongly dependent on geographic ecology. There are clear signals of epidemiological indications of expansion of ESBL E. coli and Klebsiella species in the community. This may be provoked by excessive use of antimicrobials in medical practice but also by the widespread contamination of the food chain with ESBL Enterobacteriaceae, which is also the case in countries with – until now – no extreme resistance problems, such as Denmark.[30‐32] Data from India indicate that more than half of all E. coli strains and about one-third of Klebsiella strains isolated from IAI produce ESBL.[33] Data from Hawser et al.[33] show important differences in resistance rates for E. coli and Klebsiella species among European countries, albeit that the study is unclear about the origin of infection (either community or hospital onset). Resistance rates for E. coli were highest in Turkey, Greece and Portugal, while fewer resistance problems were noted in France, Lithuania and Estonia. For Klebsiella, carbapemens appear to be a good choice for all European countries (more than 90% susceptibility), with the exception of Greece, where only 43% of isolates were susceptible for both imipenem and ertapenem. In particular, because of the huge geographic variation in resistance rates, special attention should be given to patients with a recent history of travelling in regions known to have particular resistance problems, such as India, Thailand or Egypt.[34,35] However, the extent to which antibacterial resistance in Enterobacteriaceae results in worse clinical outcomes in cases of community-acquired IAI, especially in circumstances where adequate surgical source control was promptly achieved, remains unknown.
Finally, P. aeruginosa is also a feared pathogen, the importance of which is frequently overestimated in the context of IAI. P. aeruginosa is a typically opportunistic pathogen, generally affecting immunocompromized or otherwise severely debilitated patients. Given the relatively poor ability of this micro-organism to invade tissue, the isolation of P. aeruginosa often represents contamination rather than true pathogen, especially in cases in which surgical intervention was promptly performed and infection, as such, was not established. In the large study by Swenson et al.,[21] non-fermenting Gram-negative bacteria (P. aeruginosa, S. maltophilia and A. baumannii) accounted for fewer than 6% of all IAIs. In a series of secondary peritonitis, P. aeruginosa accounted for about 9% of infections. Edelsberg et al.[36] demonstrated that, in both community-acquired and healthcare-associated IAI, coverage of Pseudomonas did not add to higher rates of clinical success, indicating the limited importance of these pathogens. Yet, in patients with a particular risk profile for opportunistic pathogens (e.g. immunocompromized patients), coverage of Pseudomonas is warranted in all cases.[37]
Coverage Against Enterococci
Enterococcal involvement in IAI is generally encountered in patients with a loaded medical history and is associated with a grim prognosis.[38‐40] Routine coverage against enterococci is not mandatory in community-acquired IAI as it appears not to give additional benefit.[41‐43] Empirical coverage of enterococci is warranted in nosocomial IAI, which, in the majority, represents cases in whom early surgical source control was not achieved or complications such as anastomotic leakage occur. Reasonable indications for enterococcal coverage include septic shock, prolonged treatment with cephalosporins, immunosuppression, presence of prosthetic heart valves and recurrent IAI with associated severe sepsis.[44‐47] When enterococcal infections are suspected, coverage should be included in the empirical regimen. Empirical therapy should primarily target Enterococcus faecalis.[24] This may require additional drugs such as ampicillin or vancomycin when cephalosporin-based regimens are prescribed. In patients with a very high risk profile (e.g. a liver transplant patient with an IAI originating from the hepatobiliary tree or a patient known to be colonized with VRE) coverage of Enterococcus faecium is recommended. In this case, tigecycline or linezolid can be prescribed.[48,49]
Coverage of Methicillin-Resistant Staphylococcus Aureus (MRSA)
The presence of MRSA may either be based on pre-infection colonization or acquisition in the hospital. MRSA is often isolated in patients with long-standing, difficult-to-treat infections such as tertiary peritonitis. Vancomycin has been used most extensively in patients with intra-abdominal MRSA infection, but other drugs with demonstrated anti-MRSA activity, such as linezolid, tigecycline, daptomycin or quinupristin/dalfopristin, can be used Clinical experience in this category of severely ill patients is limited.
Coverage Against Candida Species
With the exception of patients with a particular risk profile for fungal infections (e.g. neutropenic patients) or patients with anastomotic leakage, Candida should not be covered by the empirical regimen.[50,51] Even when initial culture results show Candida spp., the clinical relevance of these isolations remains vague and probably not all patients need antifungal coverage.[52] In a prospective cohort of 62 patients with peritonitis following peptic ulcer perforations, Candida was isolated from 37% of cases (n = 23).[53] Antifungal therapy was initiated in eight patients, of whom only three survived. Yet, all patients in whom no antifungal therapy was initiated survived. This illustrates the ambiguous role of Candida as a pathogen in IAI.
An algorithm to determine which patients may benefit from antifungal therapy has been proposed.[54] This algorithm is based on (i) presence or absence of established peritonitis; (ii) isolation of Candida spp.; (iii) presence or absence of severe sepsis or septic shock; and (iv) immunocompromized status. This algorithm, however, has not yet been subject to clinical evaluation. Invasive candidiasis is nearly always preceded by overt Candida colonization, and although the positive predictive value of prior colonization is rather low, failure to cover Candida species in the empirical phase is associated with treatment failure and death.[55,56] Therefore, in cases of overt Candida colonization prior to infection onset, or when peri-operative cultures reveal Candida species, antifungal therapy is recommended. Dupont et al.[57] developed and validated a simple score to estimate the likelihood of Candida involvement in peritonitis. This score describes risk levels of Candida involvement based on the presence or absence of four risk factors: female gender, upper gastrointestinal tract origin of peritonitis, peri-operative cardiovascular failure and previous antimicrobial therapy. The risk of Candida involvement is minimal when no or only one risk factor is present and maximal when all four are present. In the presence of three risk factors, the score had 84% sensitivity, but the 50% specificity was rather low, thereby limiting its usefulness in clinical practice.
×
![]()
3.3 Patient-Related Factors
Recent guidelines for the diagnosis and treatment of complicated IAI make use of the concept ‘high-risk patient’.[24] This concept encompasses different risk factors for treatment failure and poor outcome. The prognosis of IAI depends on the overall quality of the management of infection, which includes aspects such as timely recognition of signs and symptoms, physiological resuscitation and organ support, adequate surgical source control and prompt initiation of appropriate antimicrobial therapy. Delays in initial intervention and inability to achieve adequate debridement or drainage because of the high degree of peritoneal contamination are associated with failure of source control for IAI.[3,4] Besides aspects of infection management, patient-related factors can also compromise the odds of survival. Table IV summarizes conditions leading to an increased risk of inadequate management and subsequent death. A distinction has to be made between underlying conditions and acute conditions, or severity of disease expression.
Table IV
Table IV. Factors contributing to a high-risk profile in intra-abdominal infections
3.3.1 Underlying Co-Morbidities
Older age, low albumin level and poor nutritional status are risk factors for death following failure of source control.[11,21,24,60‐62] Yet, relationships between particular underlying conditions, involvement of resistant pathogens, inappropriate antimicrobial therapy and subsequent death have not been demonstrated so far. According to a large single-centre study including 2049 patients, complicated IAIs caused by multidrug-resistant pathogens are associated with higher mortality rates (17.0% vs 8.6%; odds ratio 2.19, 95% CI 1.53, 3.13).[21] Underlying conditions associated with the involvement of resistant pathogens were current corticosteroid use, solid organ transplant, and pulmonary and liver disease. However, these findings were not adjusted for previous antimicrobial exposure, the major risk factor for resistance. To the best of our knowledge, no underlying condition (as such HIV, chronic obstructive pulmonary disease, etc.) constitutes an increased risk of involvement of resistant pathogens. Therefore, the decision to cover resistant pathogens should essentially be based on the presence of major risk factors as indicated in the grid: recent antimicrobial exposure and/or late-onset healthcare-associated IAI.
3.3.2 Penicillin Allergy
Patients with proven allergy to penicillin should not receive ampicillin or its derivates such as amoxicillin or piperacillin/tazobactam. In cases of non-IgE-mediated allergy, cross-allergy is uncommon with cephalosporins and carbapenems, and never observed with fluoroquinolones, aminoglycosides, glycopeptides, imidazoles and linezolid. If the proposed regimen includes a penicillin derivate, it is better replaced by a cephalosporin or carbapenem. One should take into account, however, that cephalosporins have no activity against enterococci and anaerobic Gram-negative bacteria and that ertapenem does not cover Pseudomonas species. When indicated, a glycopeptide for enterococci or an imidazole for anaerobic bacteria must be prescribed. In IgE-mediated allergy, cross-reaction with cephalosporins is rare. Nevertheless, these agents should be avoided. The drug of choice in such cases is aztreonam (combined with a glycopeptide and, if necessary, an imidazole) or a fluoroquinolone (combined with an imidazole if considered necessary).[63,64] Tigecycline is another valuable option in penicillin-allergic patients.[65] Additional coverage of P. aeruginosa is, however, necessary in patients at risk for Pseudomonas involvement.
3.3.3 Severity of Disease Expression
Severity of disease expression refers to the systemic inflammatory reaction provoked by the IAI and associated organ derangements. The proposed grid differentiates between mild, moderate and severe disease expression. Basically, this correlates with the traditional sepsis classification, respectively, sepsis, severe sepsis and septic shock.[66] Hereby, sepsis is a condition characterized by a systemic inflammatory response syndrome, severe sepsis is accompanied by additional organ failure, and septic shock refers to a condition associated with arterial hypotension. The habit is to prescribe more last-line agents (typically carbapenems) in more pronounced disease expression, albeit that there is little rationale to support this practice. There is no reason to assume resistant pathogens on the basis of disease expression. As such, in the absence of true risk factors for resistance (late-onset healthcare-associated IAI and recent antimicrobial exposure), last-line antimicrobial agents cannot be recommended. However, one can assume that, in patients with moderate to severe disease expression, the margin by which one can afford inappropriate therapy is much smaller than in patients presenting with mild disease. It seems logical that the clinical consequences of inappropriate therapy will be more serious in patients with septic shock.
Using these elements to consider in selecting empirical antimicrobial therapy, a list of regimens is proposed by us. Each of these regimens falls back on the classification of IAI based on severity of disease expression (mild, moderate, severe), anatomical disruption, and community-acquired or early-onset healthcare-associated origin versus late-onset healthcare-associated origin and/or recent antimicrobial exposure (2–4 days of therapy) [table II]. Essentially, three regimens are proposed: (i) a baseline regimen without coverage of nosocomial Gram-negatives (including P. aeruginosa), enterococci or Candida species; (ii) a regimen with additional coverage of nosocomial Gram-negatives and enterococci; and (iii) a regimen with coverage of nosocomial Gram-negatives, enterococci or Candida species.
The proposed regimens are partially derived from the guidelines for the diagnosis and management of complicated IAIs and the guidelines for the treatment of invasive candidiasis.[24,59] One should realize, however, that baseline regimens often cover a broader spectrum of pathogens than strictly needed (e.g. ertapenem, tigecycline or moxifloxacin). Yet, in order not to endanger the chances of appropriate therapy, antibacterial restriction should rather be achieved through correct indications for antimicrobial therapy and avoidance of unnecessarily long duration of therapy.
×
![]()
4. Recently Introduced Agents
Recently, a number of newer drugs in different classes have been evaluated in the treatment of complicated IAI. These further expand the therapeutic options and further simplify treatment by reducing the number of administrations per day.
4.1 Doripenem
Doripenem is the newest carbapenem with a spectrum similar to that of meropenem and was approved by the US FDA for the treatment of complicated IAI in 2007. In a large randomized controlled trial, it was found to be non-inferior to meropenem.[67] Compared with imipenem/cilastatin,[68] doripenem has been reported to have increased activity to a number of Gram-negative bacteria and also emergence of resistance during treatment was found to be lower, but the clinical impact of these findings is unclear. Doripenem dose in the complicated IAI studies was 500 mg three times daily. Following its activity against Pseudomonas and ESBL-producing Enterobacteriaceae, doripenem is useful when these pathogens are a concern (table II).
Anzeige
4.2 Moxifloxacin
Moxifloxacin is a broad-spectrum fluoroquinolone that has recently been positioned as first-line agent in the treatment of IAI. It penetrates well and accumulates in gastrointestinal tissues and peritoneal fluid,[69] and has demonstrated in vitro activity against the majority of organisms involved in complicated IAIs.[70] It has been compared with several comparators, including β-lactam/lactamase inhibitors, cephalosporin-based therapy and carbapenems.[71‐73] In all these studies, non-inferiority with the comparator was found. Although an increase in resistance to moxifloxacin has been described in selected patients, this seems to be variable enough not to affect clinical efficacy. Yet it is prudent to evaluate the local resistance patterns when selecting empirical therapy for complicated IAI. Moxifloxacin is dosed at 400 mg once daily. Moxifloxacin is best positioned as first-line single-agent therapy in circumstances where fluoroquinolone-resistance of E. coli is not an issue (table II).
4.3 Tigecycline
Tigecycline belongs to a newer class of antibacterials, the glycylcyclines, and had in vitro activity against the flora commonly isolated in community-acquired complicated IAI.[74] Its spectrum does not include Pseudomonas and therefore this drug is preferably positioned as first-line single-agent therapy (table II). On the other hand, tigecycline is active against MRSA, which can be advantageous in areas with a high prevalence of MRSA. The efficacy of tigecycline was comparable to that of meropenem in a large cohort of patients with complicated IAI.[75] A drawback, however, is that a pooled analysis of 13 clinical trials for both approved and unapproved indications for tigecycline (including one trial on complicated IAI), demonstrated an increased risk of death among patients receiving tigecycline compared with patients receiving comparator antibacterials (adjusted risk difference for all-cause mortality 0.6%, 95% CI 0.1, 1.2). This observation led to a recommendation against the use of tigecycline in severe infections.[76] Following this FDA drug safety communication, we do not recommend tigecycline in patients with IAI presenting with septic shock (tables I and II).
Tigecycline dosing is 50 mg twice daily after a 100 mg loading dose. It is a valuable option for patients with penicillin allergy.
5. Directed Therapy
Once the result of cultures obtained during surgery or after percutaneous drainage are available, de-escalation of antimicrobial therapy can be considered when broad-spectrum agents have been used as empirical therapy, most notably in patients with severe community-acquired disease. It should be remembered that anaerobes are more difficult to culture and that often only the most abundant micro-organisms are documented. As most complicated IAI are polymicrobial in nature, antimicrobial regimens used in a de-escalation strategy should also cover the full spectrum of aerobic and anaerobic micro-organisms, not only the micro-organisms that have been identified. The only exception to this rule may be patients with primary peritonitis, or selected patients with postoperative abscesses with only one pathogen identified on direct examination and culture.
Anzeige
6. Duration of Antimicrobial Therapy for IAI
The duration of antimicrobial therapy should ideally be defined from the start of the treatment. In case of complicated IAI with prompt surgical intervention and adequate source control, antimicrobial therapy is generally recommended to continue for 5–7 days, but shorter courses have been proposed, most often based on the extent of the infection and clinical response of the patient to the treatment.[77] Yet, strong evidence to support such shorter courses remains scarce, especially for more severe cases. The largest body of evidence is on the duration of antimicrobials in children with acute appendicitis, where 3 days of antimicrobials seems sufficient.[78] A recent study found that adult patients with community-acquired localized peritonitis of mild to moderate severity who were treated for 3 days had similar outcomes to patients treated for 5–10 days.[79] Besides this study, the proposed duration of antimicrobial therapy in IAI is largely based on expert opinion. Table V summarizes the proposed duration of antimicrobial therapy in IAI according to the primary source of infection.[80] In patients who require (repetitive) reoperation because of failed source control, the operation in which the source is definitely controlled should be regarded as the index operation from which the duration of therapy is calculated. In selected patients, prolonged antimicrobial therapy may be necessary, especially when source control is difficult or impossible to obtain.
Table V
Table V. Duration of antimicrobial therapy according to primary site of infection[80]
×
![]()
7. Conclusion
We proposed an alternative classification of IAI based on (i) anatomical disruption; (ii) severity of disease expression; and (iii) either community-acquired/early-onset healthcare-associated origin, or late-onset healthcare-associated origin and/or recent antimicrobial exposure. All possible combinations according to these three components are summarized in a grid. The grid allows physicians to select the most convenient empirical antimicrobial regimen according to the clinical situation. More precisely, it advises on the necessity of covering P. aeruginosa or resistant Gram-negative bacteria, enterococci and yeasts, albeit that local patterns of microbial ecology should also always be taken into account. In recent years, some newer agents such as doripenem, moxifloxacin and tigecycline have been added to the antibacterial armamentarium for IAI. While moxifloxacin and tigecycline can be used as first-line single-agent therapy, doripenem can be used when Pseudomonas and or resistant Gram-negative pathogens are a concern. In patients in whom the source can be adequately controlled, antimicrobial therapy should be restricted to a short course, generally 3–7 days after surgery.
Acknowledgements
This paper was prepared without funding. Jan J. De Waele has acted as a consultant for AstraZeneca, Bayer Healthcare and Wyeth. Neither of the other authors have any conflict of interest to disclose.